Genomic Testing for Increased Confidence in Management of Favorable Intermediate Risk Prostate Cancer

Program Overview

• Review NCCN Guidelines^® around genomic testing in favorable intermediate risk (FIR) prostate cancer
• Understand the clinically heterogeneous nature of the FIR group and the importance of assessing risk of adverse pathology when active surveillance is being considered
• Review the development of the Oncotype DX^® GPS^TM assay and its demonstrated clinical utility in FIR patients.
• Review case studies to understand how an expert in the field uses the GPS assay to help inform treatment management decisions in FIR patients.